Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Account Payables
Amounts the company owes suppliers for goods and services received.
Actuate Therapeutics IncNASDAQ: ACTU
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 54.6% from a year ago
Account payables stood at $1.2M at the end of Q1 FY2026, down 54.6% from a year earlier and down 21.2% from the prior quarter. Over 3 fiscal years it compounded at -10.6% a year.
Context
- Account payables amounted to 13.5% of total assets at the end of Q1 FY2026, down 45.5 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -54.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 1.52M USD
- Year-over-year change
- -20.7%
- 3-year CAGR
- -10.6%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.52M | -20.7% |
| FY2024 | 2024-12-31 | 1.92M | -43.9% |
| FY2023 | 2023-12-31 | 3.42M | +60.6% |
| FY2022 | 2022-12-31 | 2.13M | — |
Account Payables vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -54.6% is the 5th highest of 9, against a peer median of -55.4%.
- Account payables amounts to 13.5% of total assets for ACTU, versus a peer median of 0.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $2.34M USD | +7.8% | -54.1% | 2.0% | |
| Mar 2026 | CHF 1.92M CHF | -19.9% | -2.0% | 2.2% | |
| Mar 2026 | $1.59M USD | +6.4% | +5.9% | 0.4% | |
| Mar 2026 | $1.42M USD | -38.8% | -26.1% | 0.6% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $1.2M USD | -54.6% | -10.6% | 13.5% |
| Mar 2026 | $1.04M USD | -72.1% | +42.5% | 0.2% | |
| Mar 2026 | $622K USD | -77.0% | -15.5% | 0.4% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $272K USD | -93.3% | -37.9% | 1.2% |
| Mar 2026 | $217K USD | -87.7% | +3.9% | 0.4% | |
| Peer median (excluding ACTU) | — | -55.4% | -8.8% | 0.5% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.